cepharanthine has been researched along with Disease Models, Animal in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chu, X; Ding, Y; Gao, C; Gong, W; Kong, X; Lu, C; Meng, Y; Tan, F; Zheng, J | 1 |
| He, L; Wang, HG; Wen, X; Yang, XZ; Zhang, JL; Zhang, MH; Zhang, MN | 1 |
| Chai, JR; Chen, J; Gao, JP; Liu, JG; Long, JD; Wang, YJ; Wei, XY | 1 |
| He, L; Wang, HG; Wang, JY; Wen, X; Xie, R; Yang, XZ; Zhang, MH; Zhang, MN | 1 |
| Bai, Q; Chen, P; Feng, Y; Li, Z; Liu, H; Su, G; Wang, X; Wang, Y; Xu, D; Zhang, R; Zhou, P | 1 |
| Hong, Y; Liao, L; Lin, Y; Liu, Q; Ni, J; Yu, S; Zhang, Z; Zhong, Y | 1 |
| Chen, X; Hu, G; Huang, H; Qian, A; Wang, C; Xu, H | 1 |
| Ershun, Z; Naisheng, Z; Yongguo, C; Yunhe, F; Zhengkai, W; Zhengtao, Y | 1 |
| Chapus, C; Desgrouas, C; Dormoi, J; Ollivier, E; Parzy, D; Taudon, N | 1 |
| Chang, YK; Huang, CJ; Huang, SC; Kao, MC | 1 |
| Hagiwara, S; Hasegawa, A; Koga, H; Kudo, K; Kusaka, J; Noguchi, T | 2 |
| Cox, RA; Hawkins, HK; Jodoin, JM; McGuire, RW; Murakami, K; Schmalstieg, FC; Traber, DL; Traber, LD | 1 |
| Lantvit, D; Lim, E; Pezzuto, JM; Tamez, PA | 1 |
| Furusawa, S; Wu, J | 1 |
| Murakami, K; Okajima, K; Uchiba, M | 1 |
| Bonté, F; Ferreira, ME; Fournet, A; Lavault, M; Nakayama, H; Rojas de Arias, A; Samudio, M; Schinini, A; Torres de Ortiz, S; Vera de Bilbao, N | 1 |
1 review(s) available for cepharanthine and Disease Models, Animal
| Article | Year |
|---|---|
The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Apoptosis; Benzylisoquinolines; Disease Models, Animal; Humans; Molecular Structure; Neoplasms; Shock, Septic; Tumor Cells, Cultured | 2007 |
17 other study(ies) available for cepharanthine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Cepharanthine loaded nanoparticles coated with macrophage membranes for lung inflammation therapy.
Topics: Animals; Animals, Outbred Strains; Benzylisoquinolines; Biomimetics; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Macrophages; Male; Mice; Nanoparticles; Particle Size; Pneumonia; Random Allocation; RAW 264.7 Cells | 2021 |
Cepharanthine ameliorates dextran sulphate sodium-induced colitis through modulating gut microbiota.
Topics: Animals; Benzylisoquinolines; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Microbiome; Mice; Mice, Inbred C57BL; RNA, Ribosomal, 16S | 2022 |
Antinociceptive activities and mechanism of action of Cepharanthine.
Topics: Acetates; Analgesics; Analgesics, Opioid; Animals; Benzylisoquinolines; Disease Models, Animal; Mice; Pain; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2022 |
Cepharanthine Alleviates DSS-Induced Ulcerative Colitis via Regulating Aconitate Decarboxylase 1 Expression and Macrophage Infiltration.
Topics: Animals; Benzylisoquinolines; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Humans; Macrophages; Mice; Mice, Inbred C57BL | 2023 |
Cepharanthine Hydrochloride Improves Cisplatin Chemotherapy and Enhances Immunity by Regulating Intestinal Microbes in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacteria; Benzylisoquinolines; Cell Line, Tumor; Cisplatin; Disease Models, Animal; DNA, Ribosomal; Drug Synergism; Drug Therapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gastrointestinal Microbiome; Humans; Immunity; Immunity, Innate; Intestinal Mucosa; Metagenomics; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Differentiation Factor 88; Signal Transduction; Toll-Like Receptor 4; Xenograft Model Antitumor Assays | 2019 |
Cepharanthine ameliorates titanium particle-induced osteolysis by inhibiting osteoclastogenesis and modulating OPG/RANKL ratio in a murine model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Bone-Anchored Prosthesis; Bone-Implant Interface; Cathepsin D; Disease Models, Animal; Gene Expression Regulation; Male; Mice; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; Prosthesis Failure; RANK Ligand; Skull; Tartrate-Resistant Acid Phosphatase; Titanium | 2019 |
Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Bronchoalveolar Lavage Fluid; Cell Line; Cell Survival; Dexamethasone; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; I-kappa B Proteins; Inflammation; Interleukin-1beta; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred BALB C; NF-KappaB Inhibitor alpha; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Plant Preparations; Stephania; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2014 |
Cepharanthine attenuates lipopolysaccharide-induced mice mastitis by suppressing the NF-κB signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Benzylisoquinolines; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Mammary Glands, Animal; Mastitis; Mice; Mice, Inbred BALB C; Neutrophil Infiltration; NF-kappa B; Peroxidase; Signal Transduction; Tumor Necrosis Factor-alpha | 2014 |
In vitro and in vivo combination of cepharanthine with anti-malarial drugs.
Topics: Animals; Antimalarials; Benzylisoquinolines; Disease Models, Animal; Drug Therapy, Combination; Malaria; Mice; Mice, Inbred BALB C; Parasitic Sensitivity Tests; Plasmodium berghei; Survival Analysis; Treatment Outcome | 2014 |
Cepharanthine alleviates liver injury in a rodent model of limb ischemia-reperfusion.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspartate Aminotransferases; Benzylisoquinolines; Disease Models, Animal; Extremities; Lipid Peroxidation; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2016 |
Cepharanthine exerts anti-inflammatory effects via NF-κB inhibition in a LPS-induced rat model of systemic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Cell Line; Disease Models, Animal; Inflammation; Interleukin-6; Lipopolysaccharides; Macrophages; Male; Mice; NF-kappa B; Nitrates; Nitrites; Rats; Rats, Wistar; Sepsis; Tumor Necrosis Factor-alpha | 2011 |
Cepharanthine improves renal ischemia-reperfusion injury in rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Disease Models, Animal; Kidney; Kidney Diseases; Male; Malondialdehyde; Microscopy, Electron, Transmission; Rats; Rats, Wistar; Reactive Oxygen Species; Reperfusion Injury | 2011 |
Cepharanthin, an alkaloid from Stephania cepharantha, inhibits increased pulmonary vascular permeability in an ovine model of sepsis.
Topics: Alkaloids; Animals; Benzylisoquinolines; Calcium; Capillary Permeability; Disease Models, Animal; Female; Hemodynamics; Humans; Leukocyte Count; Leukocyte Elastase; Lung; Organ Size; Platelet Count; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Gas Exchange; Sepsis; Sheep; Smoke Inhalation Injury; Stephania | 2003 |
Chemosensitizing action of cepharanthine against drug-resistant human malaria, Plasmodium falciparum.
Topics: Alkaloids; Animals; Benzylisoquinolines; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Inhibitory Concentration 50; KB Cells; Malaria, Falciparum; Male; Mice; Parasitemia; Parasitic Sensitivity Tests; Plasmodium berghei; Quinine; Verapamil | 2005 |
The prevention of lipopolysaccharide-induced pulmonary vascular injury by pretreatment with cepharanthine in rats.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Calcium; Capillaries; Capillary Permeability; Disease Models, Animal; Escherichia coli; Injections, Intraperitoneal; Interleukin-1; Leukocyte Elastase; Lipopolysaccharides; Lung; Male; Neutrophil Activation; Neutrophils; Pulmonary Circulation; Rats; Rats, Wistar; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha | 2000 |
Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model.
Topics: Acute Disease; Administration, Oral; Alkaloids; Animals; Benzylisoquinolines; Chagas Disease; Chronic Disease; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Immunoblotting; Isoquinolines; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Parasitemia; Trypanocidal Agents | 2000 |